Name: Autism, Focal Cortical Atrophy, and Epilepsy: A New Clinical Entity (en Inglés)
SKU: 66202103
Price: 60160.00 CLP
Availability: InStock
Author: Al-Mosawi, Aamir
ISBN: 9786205502204

portada Autism, Focal Cortical Atrophy, and Epilepsy: A New Clinical Entity (en Inglés)

Autism, Focal Cortical Atrophy, and Epilepsy: A New Clinical Entity (en Inglés)

Formato

Libro Físico

Editorial

LAP Lambert Academic Publishing

Autor

Al-Mosawi, Aamir

Idioma

Inglés

N° páginas

Encuadernación

Tapa Blanda

Dimensiones

22.9x15.2x0.4 cm

ISBN13

9786205502204

Autism, Focal Cortical Atrophy, and Epilepsy: A New Clinical Entity (en Inglés)

Al-Mosawi, Aamir (Autor) · LAP Lambert Academic Publishing · Tapa Blanda

Libro Nuevo Importado

Envío: 20 a 24 días háb.

$ 109.390$ 60.160

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 10 unidades

$ 60.160

Llega entre el 29 Sep y el 05 Oct a Santiago, Región Metropolitana. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Autism, Focal Cortical Atrophy, and Epilepsy: A New Clinical Entity (en Inglés)"

Autism disorders are a heterogeneous group of disorders that are typically considered a functional neurodevelopmental disorder without consistent radiological findings. Consequently, routine brain imaging is not widely recommended. For decades, autism disorders have been considered life-long disorders without curative therapies. Recently, a new therapeutic approach aiming primarily at improving and curing the two major diagnostic features of autism which are poor responsiveness to their name and poor eye contact, has been increasingly used. Injectable cerebrolysin is the main therapeutic component in this new therapeutic approach. This book highlights a unique clinical entity where early childhood autism is associated with focal cortical atrophy and later development of epilepsy. The initial response to cerebrolysin underscores the role of neurotrophic therapy in modulating neuroplasticity and improving functional outcomes even in patients with underlying structural abnormalities. The recurrence of symptoms and emergence of seizures following treatment cessation suggests a progressive or evolving neurological basis rather than a purely static neurodevelopmental disorder.